<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605226</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-CIH-IR-004</org_study_id>
    <nct_id>NCT02605226</nct_id>
  </id_info>
  <brief_title>Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer</brief_title>
  <acronym>CRYO-PCA-III</acronym>
  <official_title>A Prospective Multi-center Study to Compare the QOL and Efficacy of External Beam Radiation Therapy or Cryoablation Therapy for Stage III Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is going to evaluate tumor control and quality of life in patients with prostate
      cancer treated with radiotherapy or cryoablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the tumor control in patients with prostate cancer treated with
           radiotherapy or cryoablation

        -  To determine the quality of life of these patients. OUTLINE: This is a multicenter
           study. Patients are stratified according to Gleason score (≥ 8 vs 7 vs ≤ 6), persistent
           prostatic specific antigen (PSA) at allocation (&gt; 0.5 ng/mL vs ≤ 0.5 ng/mL),
           participating center. Patient are allocated to two treatment arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median PSA progression-free survival in patients responding to the study treatments</measure>
    <time_frame>Within 12 months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life impact of treatments' side effects measured by change in EORTC QOL－C30 from baseline to 3, 6 and 12 months after treatment</measure>
    <time_frame>3, 6 and 12 months after treatment</time_frame>
    <description>European Organization for Research and Treatment of Cancer(EORTC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
Patients receive cryoablation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation therapy</intervention_name>
    <description>Cryoablation therapy</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiation therapy</intervention_name>
    <description>External beam radiation therapy</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <description>bicalutamide</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>luteinizing-hormone releasing-hormone (LHRH) agonist</intervention_name>
    <description>luteinizing-hormone releasing-hormone (LHRH) agonist</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate adenocarcinoma, T3aN0M0, T3bN0M0

          -  Previously untreated disease or undergone endocrine therapy without reaching to
             castration resistant prostate cancer

          -  Survival ≥ 12 months

          -  WHO performance status 0-2

          -  white blood cell ≥ 3.5 ×10*9/L

          -  Platelets ≥ 5×10*9/L

          -  Hemoglobin ≥ 10 g/dL

        Exclusion Criteria:

          -  History of malignant disease

          -  History of coronary artery disease

          -  Uncontrolled infection

          -  Other concurrent severe or uncontrolled medical disease that could compromise
             participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac
             disease, uncontrolled hypertension, congestive cardiac failure, ventricular
             arrhythmias, active ischemic heart disease, myocardial infarction within the past six
             months, chronic liver or renal disease, and active upper gastrointestinal tract
             ulceration)

          -  Psychological, familial, sociological, or geographical condition potentially hampering
             compliance with the study treatment and follow-up schedule
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Guo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institue and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi Guo, PhD</last_name>
    <phone>02223340123</phone>
    <phone_ext>1095</phone_ext>
    <email>cjr.guozhi@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xueling Yang, PhD</last_name>
    <phone>02223340123</phone>
    <phone_ext>1095</phone_ext>
    <email>yxueling123@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Guo, MD</last_name>
      <phone>13920076145</phone>
      <email>cjr.guozhi@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Haipeng Yu, MD</last_name>
      <phone>13352070835</phone>
      <email>jieruke@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Wenge Xing, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

